<DOC>
	<DOCNO>NCT00307749</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety three dos MCC-257 patient mild moderate diabetic polyneuropathy</brief_summary>
	<brief_title>Safety Efficacy MCC-257 Treatment Diabetic Polyneuropathy</brief_title>
	<detailed_description>The study use double-blind , randomize , placebo-controlled , fixed-dose , parallel-group design . Patients randomize equally 1 4 treatment group : MCC-257 20 mg , MCC-257 40 mg , MCC-257 80 mg , placebo , give daily 24 week . The study consist 2 period : 1 ) screening period 21 day prior baseline , include formal screening visit ; 2 ) 24-week treatment period , patient take study treatment , various assessment perform 4 visit .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>The patient male female , 1870 year age The patient either type 1 type 2 diabetes The patient mild moderate diabetic neuropathy The patient free clinically significant illness disease , determine medical history , physical examination , laboratory evaluation , safety test Being treat anticoagulant aspirin , warfarin , digoxin , Plavix BMI &gt; 40 A significant disorder condition diabetes cause symptom physical condition mimic peripheral neuropathy interfere cognition Any proximal neuropathy , clinically evident nerve entrapment , focal trauma potentially affect nerve function Women childbearing potential refrain sexual activity use adequate contraception Pregnant lactate woman An ALT AST value &gt; 2X upper limit normal ( ULN ) Clinically significant cardiovascular disease within last six ( 6 ) month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Neuropathy</keyword>
	<keyword>Nerve Conduction</keyword>
</DOC>